We used an enzyme-linked immunoabsorbent assay to measure creatine kinase (CK; EC 2.7.3.2) BB in the sera of 58 cancer patients. A pre-incubation step with an anti-CK-M antibody-coated bead removed M chain components, and CK-BB was quantified with use of an anti-CK-B antibodycoated tube. No cross reactivity was observed with mitochondrial CK or CK-MM; CK-MB cross reacted slightly (1.6%). Macro CK type 1 was measured as CK-BB. Average analytical recovery of purified CK-BB added to serum was 97.7%. Although the enzyme activity of CK-BB is labile, our studies show that this protein is antigenically stable for 12 months when stored frozen. The upper limit of normal for CK-BB concentration was 0.3 ug/L (95th percentile, n = 25). Of the 20 cases of breast cancer of various stages, none showed any increases of serum CK-BB. Only two of 18 patients with prostatic carcinoma (stage 0), and two of 10 patients with oat-cell carcinoma of the lung had increased concentrations of CK-BB in the serum. Ten patients with squamous cell cancer of the lung had normal concentration of the enzyme. Thus the CK-BB isoenzyme is not frequently increased in cancers of the prostate, lung, and breast, and it has little apparent value as a tumor marker for these diseases.
discrepancies
in the incidence of increased CK-BB concentration in cancer patients.
To clarify the potential usefulness of CK-BB as a marker, we used a solid-phase enzyme immunoassay that is specific for CK-BB through use of polyclonal antibodies directed against the B polypeptide chain of CK. Using this immunoassay, we investigated the incidence of increased CK-BB concentrations in sera of patients with cancer of the breast, lung, or prostate.
MaterIals and Methods

Subjects:
Sera from 58 patients who had been admitted for evaluation and treatment of cancer of the breast, lung, or prostate at the M.D. Anderson Hospital and Tumor Institute were collected and stored frozen at -20 #{176}C until assay. We also assayed blood samples from 25 normal healthy individuals to establish a reference interval for CK-BB, and we used serum specimens containing macro CK types 1 and 2 to assess cross reactivity of these atypical isoenzymes with the CK-BB antiserum.
Reagents:
Tubes coated with polyclonal antibody to CK-B, and diluent, washing solution, buffer, substrate chromogen, and the 250 mmol/L H2S04 stopping solution were from the Enzygnost CK-MB kit (Behring Diagnostics, La Jolla, CA 91037). Beads coated with monoclonal antibody to CK-M were from the "Tandem" CK-MB kit (Hybritech, San Diego, CA 92121). Polyclonal anti-CK-B antibody conjugated to horseradish peroxidase (HRP; EC 1.11.1.7) and the free CK-BB standards were from Behring Diagnostics. We used "ID Zone" (Beckman Instruments, Fullerton, CA 92634) as a serum-based quality control material for both the electrophoretic and immunoassay methods. For cross reactivity studies we used purified human CK-MM, CK-MB, and mitochondrial CK, as isolated by the procedure of Roberts and Grace (12) . We measured enzymatic activity by using "CK-NAC (UV)" reagent (Boehringer Mannheim Diagnostics, Indianapolis, IN 46250) and a "Multistat ifi" centrifugal analyzer (Instrumentation Laboratory, Lexington, MA 02173).
Electrophoresis:
We also analyzed all sera by agarose gel electrophoresis, using the Paragon system (Beckman Instruments) according to the manufacturer's directions.
Results
Precision:
The between-and within-assay precision we obtained with the quality-control samples is shown in Table  1 . The concentration of the CK-BB standards ranged from
to 75 yg/L (nglmL).
Analytical recovery: We added various amounts of CK-BB to a serum specimen to determine whether any CK-BB is lost during the two-step immunoassay procedure. The results (Table 2) showed that from 90.9 to 101.1% (average, 97.7%) of immunological activity was accounted for. Immunological stability of CK-BB in serum. Repeated freezing (at -20 #{176}C) and thawing (4#{176}C) of a CK-BB sample up to five times did not cause any significant decrease in the amount of CK-BB measured; moreover, the CK-BB concentration in the sample was stable for at least 12 months when frozen at -20 #{176}C. In contrast, incubation of a sample at 37#{176}C caused detectable decreases in both enzymatic and immunological activity. When the enzyme activity of one serum sample was decreased by incubation at 37#{176}C, first to 66% and then to 45% of its original activity, the immunological activity of the sample decreased to 92% and 72%, respective-
Cross reactivity:
Purified preparations of mitochondrial CK and CK-MM were not detectable by our assay as CK-BB. Similarly, the immunoassay method detected no CK-BB in samples that showed only CK-MM or macroCK type 2(13) by electrophoresis.
One serum sample that contained macro CK type 1 (immunoglobulin-bound Elecfrophoresis on agarose gel: We determined the detection limit for the electrophoresis method for CK-BB to be about 4 j.tg/L; i.e., samples with a CK-BB concentration greater than this demonstrated a clearly discernible band by electrophoresis.
To confirm the identity of this band, we observed its absence from samples pro-incubated with CK-BB antiserum.
No samples that had normal concentrations 
DIscussion
The sandwich-type enzyme immunoassay for measuring CK-BB in serum provides an alternative to the radioimmunoassay method previously used to investigate CK-BB in cancer patients (1-10) . The suitable analytical precision, specificity, analytical recovery, and low cross reactivity of this independent approach enabled us to re-examine the incidence of abnormal concentrations of CK-BB in serum from cancer patients.
Only four of the 58 cancer patients had significant increases of CK-BB in their serum (Figure 1) . CK-BB was confirmed by electrophoresis before and after immunoprecipitation with anti-CK-B antisera in three of the four samples with increased CK-BB. No CK-BB band was detected in the fourth sample (CK-BB = 3.1 pg/L) or in the other 54 samples. To substantiate further the absence of CK-BB from these sera, we re-assayed the sera, substituting in the assay system an alkaline phosphatase (EC 3.1.3.1)-conjugated monoclonal antibody to CK-B for the HRP-conjugated polyclonal antibody to CK-B. The same results were obtained (data not shown).
We think it particularly important to note that the low incidence of increased CK-BB is probably not the result of loss of CK-BB immunological reactivity. Although reports during storage (14) , but can be reactivated by adding thiols and chelating agents after collection (15) , our experiments suggest that CK-BB is antigenically stable for at least 12 months under these conditions.
Soon after the initial report that CK-BB may be useful as a tumor marker
(1), the reported incidence of abnormal concentrations of CK-BB in cancer patients has steadily declined. For example, Meroer and Talamo (7) did not find CK-BB useful as part of a tumor marker panel for colorectal cancer; Blick et al. (16) found BB to be a poor predictor for prostatic cancer; and Fritsche et al. (17) recently demonstrated that serum CK-BB did not consistently correlate with the clinical status of patients with progressive breast cancer. These results are consistent with the present findings that CK-BB in serum is infrequently found in high concentrations in patients with cancer of the prostate, breast, or lung, even when disease is extensive. Because our assay procedure also detects macroCK type 1, we presume that this variant is also probably not a useful marker of neoplastic diseases.
Earlier reports of increased CK-BB may reflect cross reactivity of the antisera with other CK isoenzymes (e.g., macroCK type 2) in those radioimmunoassays.
If such is the case, then macro CK type 2 may be a more useful tumor marker than CK-BB. Several recent reports support this speculation (13, 18). It might be worthwhile to investigate this particular isoenzyme in more detail.
